PHARNEXT: Pharnext refocuses its clinical trial programs on PXT3003, its most promising drug candidate, to optimize financial resources allocation

PARIS, France, February 14th, 2023, 08:30 am CET - Pharnext SA (FR001400BV89 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative

Related Keywords

United States ,Paris ,France General ,France ,Dennis Riedl ,Mary Jane Elliott ,Fabreguettes Leib ,Deborah Schwartz ,Hugo Brugi ,Alexandra Harrison ,Sukaina Virji ,Financial Press Relations ,Relations International ,Company Board Of Directors ,Consilium Strategic Communications ,Amyotrophic Lateral Sclerosis ,Euronext Growth ,Neuroscience Res ,Pharnext ,Refocuses ,Linical ,Trial ,Programs ,Xt3003 ,Most ,Romising ,Drug ,Candidate ,Optimize ,Financial ,Resources ,Allocation ,